GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Roche Holding AG (OTCPK:RHHBF) » Definitions » Valuation Rank

Roche Holding AG (Roche Holding AG) Valuation Rank


View and export this data going back to 2009. Start your Free Trial

What is Roche Holding AG Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Roche Holding AG Valuation Rank Related Terms

Thank you for viewing the detailed overview of Roche Holding AG's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Roche Holding AG (Roche Holding AG) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Roche Holding AG (OTCPK:RHHBF) » Definitions » Valuation Rank
Comparable Companies
XSWX:NOVN XSWX:COPN LLY JNJ MRK ABBV LSE:AZN PFE AMGN XPAR:SAN BMY GILD LSE:GSK TSE:4519 TSE:4568 SHSE:600276 BIIB XTER:BAYN TSE:4578 SHSE:600436
Traded in Other Exchanges
RHHVF:USA RHHBY:USA ROG N:Mexico ROz:UK ROGz:UK 0QOK:UK RHO6:Germany ROG:Switzerland RO:Switzerland
Address
Grenzacherstrasse 124, Basel, CHE, 4070
Website
https://www.roche.com
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's best-selling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.